Cohance Lifesciences Q1FY27 Revenue ₹422.3 crore, Down 23.1% YoY
Cohance Lifesciences reported Q1FY27 revenue of ₹422.3 crore, down 23.1% YoY. Adjusted EBITDA was ₹9.2 crore. The company expects improvement in Q2 and a return to growth in H2 FY27. Strategic priorities include integrating the nucleic-acid business and repositioning Agrochemicals. Consolidated net cash stood at ₹251.2 crore.
The revenue decline and margin contraction are significant negative factors. However, the company's guidance for improvement in the latter half of the year and strategic initiatives to drive future growth mitigate the immediate impact to medium.
The company reported a significant year-on-year decline in revenue and a contraction in gross margins and EBITDA, which is a negative development. Although management expresses optimism for the second half of the fiscal year, the current quarter's performance is weak.
Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) announced its unaudited financial results for the first quarter ended June 30, 2026. The company reported revenue from operations of ₹422.3 crore ($4,223 million), a year-on-year decrease of 23.1%. Gross margins contracted to 71.5% from 73.0% in Q1FY26, attributed to product mix and a lower contribution from the CDMO business (38%), reflecting the lumpy nature of the business and phasing of orders towards the second half of the fiscal year.
Adjusted EBITDA stood at ₹9.2 crore ($92 million). The reduction is due to the lower revenue base, negative operating leverage, and the impact of subsidiary consolidation. Standalone Adjusted EBITDA margins were 9.2%. The standalone business generated revenue of ₹359.9 crore ($3,599 million) and adjusted EBITDA of ₹33.2 crore ($332 million). Sapala contributed revenue of approximately ₹27.4 crore ($274 million), while NJ Bio reported revenue of ₹35.0 crore ($350 million) and an adjusted EBITDA loss. Capital expenditure during the quarter was approximately ₹59.8 crore ($598 million), and consolidated net cash stood at approximately ₹251.2 crore ($2,512 million) as of June 30, 2026.
Mr. Umang Vohra, Executive Chairman and Group CEO, stated that Q1 was expected to be the weakest quarter, and the company anticipates improvement in Q2 and a return to year-on-year growth from the second half, supported by secured orders and scheduled deliveries. Strategic priorities include building an integrated nucleic-acid business with a clear path to full ownership of Sapala and repositioning Agrochemicals towards an innovator-product-led portfolio. The company also highlighted progress in its Pharma CDMO business with scheduled deliveries for two recently commercialized molecules, a significant restocking order for a commercial molecule, and advancements in its late-stage pipeline, particularly in ADC payload-linker segments and Oligo. Cohance also achieved an EcoVadis Gold Rating and received the British Safety Council International Safety Award 2026 (Merit) for its API and CDMO sites.
What to do with a filing like this
Cohance Lifesciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Cohance Lifesciences Limited. Read the original for the full detail.